Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents

Hiroto Araki, Nadim Mahmud, Mohammed Milhem, Rafael Nunez, Mingjiang Xu, Craig A. Beam, Ronald Hoffman

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Objective. We investigated whether the addition of two chromatin-modifying agents, 5-aza-2′-deoxycytidine (5azaD) and trichostatin A (TSA), to cord blood (CB) CD34+ cells in culture results in expansion of the numbers of severe combined immunodeficient (SCID) repopulating cells (SRC). Materials and Methods. Human CB CD34+ cells were cultured with cytokines in the presence or absence of 5azaD/TSA. After 9 days of culture, the fold expansion of CD34+ and CD34+CD90+ cell numbers, colony-forming unit (CFU)-mix, cobblestone area-forming cell (CAFC), and SRC numbers were determined. Results. A 12.5-fold expansion of CD34 +CD90+ cells was observed in the 5azaD/TSA-treated cultures in comparison to the input cell numbers. Expansion of CD34 +CD90+ cells was associated with a 9.8-fold increase in the numbers of CFU-mix and 11.5-fold increase in CAFC. 5azaD/TSA treatment of the CB CD34+ cells resulted in a 9.6-fold expansion of the absolute number of SRC following 9 days of culture as determined by limiting dilution analysis. Expansion of cells maintaining CD34+CD90+ phenotype was not due to the retention of a quiescent population of cells because all of the CD34+CD90+ cells in the culture had undergone cellular division. 5azaD/TSA-treated CD34+CD90+ cells, but not CD34+CD90- cells were responsible for in vivo hematopoietic repopulation potential of nonobese diabetic/SCID mice. Conclusion. Ex vivo expansion strategy using chromatin-modifying agents provides a potential avenue by which to expand the number of hematopoietic stem cells (HSC) with a single CB unit for use as an alternative source of HSC grafts for adult recipients.

Original languageEnglish (US)
Pages (from-to)140-149
Number of pages10
JournalExperimental Hematology
Volume34
Issue number2
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

decitabine
Fetal Blood
Chromatin
trichostatin A
Blood Cells
Cell Count
Hematopoietic Stem Cells
Stem Cells
Cell Culture Techniques
SCID Mice
Cytokines
Transplants
Phenotype

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Araki, H., Mahmud, N., Milhem, M., Nunez, R., Xu, M., Beam, C. A., & Hoffman, R. (2006). Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. Experimental Hematology, 34(2), 140-149. https://doi.org/10.1016/j.exphem.2005.10.002

Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. / Araki, Hiroto; Mahmud, Nadim; Milhem, Mohammed; Nunez, Rafael; Xu, Mingjiang; Beam, Craig A.; Hoffman, Ronald.

In: Experimental Hematology, Vol. 34, No. 2, 02.2006, p. 140-149.

Research output: Contribution to journalArticle

Araki, H, Mahmud, N, Milhem, M, Nunez, R, Xu, M, Beam, CA & Hoffman, R 2006, 'Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents', Experimental Hematology, vol. 34, no. 2, pp. 140-149. https://doi.org/10.1016/j.exphem.2005.10.002
Araki, Hiroto ; Mahmud, Nadim ; Milhem, Mohammed ; Nunez, Rafael ; Xu, Mingjiang ; Beam, Craig A. ; Hoffman, Ronald. / Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. In: Experimental Hematology. 2006 ; Vol. 34, No. 2. pp. 140-149.
@article{568a205f547649a385d4de2de5761853,
title = "Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents",
abstract = "Objective. We investigated whether the addition of two chromatin-modifying agents, 5-aza-2′-deoxycytidine (5azaD) and trichostatin A (TSA), to cord blood (CB) CD34+ cells in culture results in expansion of the numbers of severe combined immunodeficient (SCID) repopulating cells (SRC). Materials and Methods. Human CB CD34+ cells were cultured with cytokines in the presence or absence of 5azaD/TSA. After 9 days of culture, the fold expansion of CD34+ and CD34+CD90+ cell numbers, colony-forming unit (CFU)-mix, cobblestone area-forming cell (CAFC), and SRC numbers were determined. Results. A 12.5-fold expansion of CD34 +CD90+ cells was observed in the 5azaD/TSA-treated cultures in comparison to the input cell numbers. Expansion of CD34 +CD90+ cells was associated with a 9.8-fold increase in the numbers of CFU-mix and 11.5-fold increase in CAFC. 5azaD/TSA treatment of the CB CD34+ cells resulted in a 9.6-fold expansion of the absolute number of SRC following 9 days of culture as determined by limiting dilution analysis. Expansion of cells maintaining CD34+CD90+ phenotype was not due to the retention of a quiescent population of cells because all of the CD34+CD90+ cells in the culture had undergone cellular division. 5azaD/TSA-treated CD34+CD90+ cells, but not CD34+CD90- cells were responsible for in vivo hematopoietic repopulation potential of nonobese diabetic/SCID mice. Conclusion. Ex vivo expansion strategy using chromatin-modifying agents provides a potential avenue by which to expand the number of hematopoietic stem cells (HSC) with a single CB unit for use as an alternative source of HSC grafts for adult recipients.",
author = "Hiroto Araki and Nadim Mahmud and Mohammed Milhem and Rafael Nunez and Mingjiang Xu and Beam, {Craig A.} and Ronald Hoffman",
year = "2006",
month = "2",
doi = "10.1016/j.exphem.2005.10.002",
language = "English (US)",
volume = "34",
pages = "140--149",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents

AU - Araki, Hiroto

AU - Mahmud, Nadim

AU - Milhem, Mohammed

AU - Nunez, Rafael

AU - Xu, Mingjiang

AU - Beam, Craig A.

AU - Hoffman, Ronald

PY - 2006/2

Y1 - 2006/2

N2 - Objective. We investigated whether the addition of two chromatin-modifying agents, 5-aza-2′-deoxycytidine (5azaD) and trichostatin A (TSA), to cord blood (CB) CD34+ cells in culture results in expansion of the numbers of severe combined immunodeficient (SCID) repopulating cells (SRC). Materials and Methods. Human CB CD34+ cells were cultured with cytokines in the presence or absence of 5azaD/TSA. After 9 days of culture, the fold expansion of CD34+ and CD34+CD90+ cell numbers, colony-forming unit (CFU)-mix, cobblestone area-forming cell (CAFC), and SRC numbers were determined. Results. A 12.5-fold expansion of CD34 +CD90+ cells was observed in the 5azaD/TSA-treated cultures in comparison to the input cell numbers. Expansion of CD34 +CD90+ cells was associated with a 9.8-fold increase in the numbers of CFU-mix and 11.5-fold increase in CAFC. 5azaD/TSA treatment of the CB CD34+ cells resulted in a 9.6-fold expansion of the absolute number of SRC following 9 days of culture as determined by limiting dilution analysis. Expansion of cells maintaining CD34+CD90+ phenotype was not due to the retention of a quiescent population of cells because all of the CD34+CD90+ cells in the culture had undergone cellular division. 5azaD/TSA-treated CD34+CD90+ cells, but not CD34+CD90- cells were responsible for in vivo hematopoietic repopulation potential of nonobese diabetic/SCID mice. Conclusion. Ex vivo expansion strategy using chromatin-modifying agents provides a potential avenue by which to expand the number of hematopoietic stem cells (HSC) with a single CB unit for use as an alternative source of HSC grafts for adult recipients.

AB - Objective. We investigated whether the addition of two chromatin-modifying agents, 5-aza-2′-deoxycytidine (5azaD) and trichostatin A (TSA), to cord blood (CB) CD34+ cells in culture results in expansion of the numbers of severe combined immunodeficient (SCID) repopulating cells (SRC). Materials and Methods. Human CB CD34+ cells were cultured with cytokines in the presence or absence of 5azaD/TSA. After 9 days of culture, the fold expansion of CD34+ and CD34+CD90+ cell numbers, colony-forming unit (CFU)-mix, cobblestone area-forming cell (CAFC), and SRC numbers were determined. Results. A 12.5-fold expansion of CD34 +CD90+ cells was observed in the 5azaD/TSA-treated cultures in comparison to the input cell numbers. Expansion of CD34 +CD90+ cells was associated with a 9.8-fold increase in the numbers of CFU-mix and 11.5-fold increase in CAFC. 5azaD/TSA treatment of the CB CD34+ cells resulted in a 9.6-fold expansion of the absolute number of SRC following 9 days of culture as determined by limiting dilution analysis. Expansion of cells maintaining CD34+CD90+ phenotype was not due to the retention of a quiescent population of cells because all of the CD34+CD90+ cells in the culture had undergone cellular division. 5azaD/TSA-treated CD34+CD90+ cells, but not CD34+CD90- cells were responsible for in vivo hematopoietic repopulation potential of nonobese diabetic/SCID mice. Conclusion. Ex vivo expansion strategy using chromatin-modifying agents provides a potential avenue by which to expand the number of hematopoietic stem cells (HSC) with a single CB unit for use as an alternative source of HSC grafts for adult recipients.

UR - http://www.scopus.com/inward/record.url?scp=31844449339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31844449339&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2005.10.002

DO - 10.1016/j.exphem.2005.10.002

M3 - Article

C2 - 16459182

AN - SCOPUS:31844449339

VL - 34

SP - 140

EP - 149

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 2

ER -